| |
|
|
RICHMOND, VA. - Boehringer Ingelheim Pharmaceuticals is planning a new 16-researcher R&D lab for pharmaceutical synthesis in Richmond's Virginia Biotechnology Research Park. Over the next five years, Boehringer plans to invest $2.5 million in the facility. Based in Germany, Boehringer's U.S. headquarters are in Connecticut.
|
|
 |
Would you like information like this delivered to your email inbox? Subscribe to Tradeline Updates to keep abreast of the latest conference developments, industry news, best practices and more! Sign Up Now!
|
|
Printer Friendly Version
Send to a Friend
